Seeking Alpha
08 Apr 2026, 17:26 UTC · 32w ago
Why Mesoblast's Move Into DMD Warrants A Speculative Buy (Upgrade)
Impact · against what's priced in
MESO is upgraded to a speculative buy based on Ryoncil's transition to a registrational trial for DMD and strong pediatric SR-aGVHD sales. The $2B peak sales potential for the DMD indication represents a significant valuation catalyst that is not currently reflected in the stock price.
- MESO+0.70
No priced-in read yet
- In context
The advancement of Ryoncil into a registrational trial for DMD with a modeled $2B peak sales potential and $1.18B risk-adjusted NPV provides a material growth catalyst beyond current commercial operations.
Read from the article alone





